Belluscura PLC signs first US distribution agreement

Belluscura PLC signs first US distribution agreement 1

LONDON, U.K: Belluscura plc, a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that, as anticipated, it has signed its first US distribution agreement for its X-PLO2R portable oxygen concentrator (POC) portfolio.

This is the first stage in establishing US-wide distribution coverage as part of the Group’s commercialisation strategy.

The distributor, located on the East Coast of the United States, is an established nationwide seller of supplemental oxygen equipment. The distributor has immediately issued its first purchase order with anticipated delivery of the first X-PLO2R portable oxygen concentrators expected in Q3 of this year.

As described in the Company’s Admission Document, Belluscura’s plan is to appoint distributors in the US to give US-wide coverage for the launch of the X-PLO2R; and this is expected to occur in the second half of 2021 and into 2022.

The X-PLO₂R weighs less than 1.5kg (3.25lbs) and the Directors believe it is the world’s first modular portable oxygen concentrator and that it will generate more oxygen by weight than any other US Food & Drug Administration (“FDA”) cleared POC in its class. The X-PLO2R can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as Chronic Obstructive Pulmonary Disease and respiratory distress caused by COVID-19. The X-PLO₂R is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices.

In March 2021 Belluscura received 510(k) clearance from the FDA for the X-PLO2R, which will be launched commercially in Q3 2021. Additional products within the range will be launched within the next 12 months.

Robert Rauker, CEO of Belluscura plc, said: “We are very pleased with the reception the X-PLO2R portable oxygen concentrator has received from distributors. We look forward to commercial launch in Q3 of 2021 and we anticipate signing a number of additional distribution agreements in the very near future.”

Belluscura PLC LON: BELL

52.00 GBX+2.50 (5.05%)today

22 Jun, 11:22 am GMT+1 ·Disclaimer

www.belluscura.com

Leave a Reply

Your email address will not be published. Required fields are marked *